Dr Adil Duru
I received my Ph.D. from the Center for Infectious Medicine (CIM), Karolinska Institutet (KI), Sweden, in 2012 where I studied MHC-class I restricted-peptide based immunomodulation of T cells and NK cells. I moved for my post-doctoral studies at the Center for Hematology and Regenerative Medicine (HERM) at KI with a focus on developing novel cell culture agents and methods as well as genetic modification strategies for ex vivo NK cell expansion. In parallel, I investigated the impact of novel immunomodulatory drugs and biological agents on prognosis and treatment of multiple myeloma patients.
From 2015 until 2020, I continued my research as an Assistant Professor/Group Leader at the Nova Southeastern University (NSU) Cell Therapy Institute, FL, USA, in the field of tumor immunology and immunotherapy with a specific interest in investigating NK cell interactions with different primary solid tumour models such as Melanoma and Sarcoma and developing novel TCR- and CAR-based genetically modified NK cell immunotherapies. Furthermore, I established and directed the Cell Therapy Core Facility (CTC) at NSU, which is capable of design, development, pre-clinical evaluation and optimization of cell therapy products. Additionally, I am a cofounder and shareholder of the biotech company Vycellix, which is focused on developing innovative products enhancing the immune responses against cancer.
In 2020, I joined to Glycostem Therapeutics, Netherlands, as senior research manager where I am working to develop novel robust and efficient native and engineered NK cell-based immunotherapy regimens for high-risk cancers.
Alicia Bertolotti
Mike Griffiths
Robert Frykberg
Laurent Decory
Gadi Borkow
Brian Pastor
Anthony Tickner
Kyle Wu
